http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020171374-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3584903efe1babebbd056e855a2cc2b3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2020-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06e14855109caac9ead3badf1cf6032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7eb0a6eb2d3c2c815b3e0caeec1a9fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a8c46bf0ed0e60df8c8533624f81231 |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020171374-A1 |
| titleOfInvention | Pharmaceutical composition comprising rivoceranib for inhibition of ocular neovascularization and method for inhibiting ocular neovascularization by using same |
| abstract | The present invention relates to a pharmaceutical composition comprising rivoceranib for inhibition of ocular neovascularization and a method for inhibiting ocular neovascularization by using same. An eye drop comprising rivoceranib as an active ingredient reduces a neovascularized corneal area and vascularity index in an animal model and the number and area of vessels and lymphatic ducts in corneal tissues and as such, can be effectively used for inhibiting corneal neovascularization. |
| priorityDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.